Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis
10.3969/j.issn.1001-5256.2023.01.031
- VernacularTitle:直接口服抗凝药物在肝硬化并发门静脉血栓中的治疗进展
- Author:
Shimei WANG
1
;
Liping WU
1
;
Ling HU
1
Author Information
1. Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, China
- Publication Type:Review
- Keywords:
Liver Cirrhosis;
Anticoagulants;
Rivaroxaban
- From:
Journal of Clinical Hepatology
2023;39(1):199-203
- CountryChina
- Language:Chinese
-
Abstract:
Portal vein thrombosis is one of the common complications of liver cirrhosis, and anticoagulation is currently the main treatment method for this disease. Since low-molecular-weight heparin must be injected and vitamin K antagonists require regular monitoring of international normalized ratio (INR), direct oral anticoagulants have become a research hotspot in replacement therapy with the advantages of convenient oral administration, no need for INR monitoring, and high recanalization rate. This article summarizes the advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis, in order to lay a foundation for further clinical studies.
